Gilead Sciences, Inc. $GILD Shares Acquired by Chicago Capital LLC

Chicago Capital LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,121 shares of the biopharmaceutical company’s stock after acquiring an additional 113 shares during the quarter. Chicago Capital LLC’s holdings in Gilead Sciences were worth $457,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of GILD. Price T Rowe Associates Inc. MD grew its position in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. Nuveen LLC acquired a new position in Gilead Sciences during the 1st quarter worth $620,415,000. Kingstone Capital Partners Texas LLC acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC raised its stake in shares of Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $117.17.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $111.00 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $82.82 and a 1 year high of $121.83. The firm has a market cap of $137.73 billion, a P/E ratio of 22.11, a PEG ratio of 0.77 and a beta of 0.36. The stock has a fifty day moving average price of $114.52 and a two-hundred day moving average price of $109.91. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares in the company, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the transaction, the insider directly owned 113,193 shares of the company’s stock, valued at $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock worth $9,402,130. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.